CN104411690A - 作为lpar拮抗剂的取代的吡唑化合物 - Google Patents

作为lpar拮抗剂的取代的吡唑化合物 Download PDF

Info

Publication number
CN104411690A
CN104411690A CN201380032266.8A CN201380032266A CN104411690A CN 104411690 A CN104411690 A CN 104411690A CN 201380032266 A CN201380032266 A CN 201380032266A CN 104411690 A CN104411690 A CN 104411690A
Authority
CN
China
Prior art keywords
phenyl
methyl
pyrazol
acid
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380032266.8A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·迪姆斯·加布里埃尔
马修·迈克尔·汉密尔顿
钱义民
阿奇尤特哈拉·西杜瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48656033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104411690(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN104411690A publication Critical patent/CN104411690A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380032266.8A 2012-06-20 2013-06-17 作为lpar拮抗剂的取代的吡唑化合物 Pending CN104411690A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661958P 2012-06-20 2012-06-20
US61/661,958 2012-06-20
PCT/EP2013/062458 WO2013189862A1 (en) 2012-06-20 2013-06-17 Substituted pyrazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
CN104411690A true CN104411690A (zh) 2015-03-11

Family

ID=48656033

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380032266.8A Pending CN104411690A (zh) 2012-06-20 2013-06-17 作为lpar拮抗剂的取代的吡唑化合物

Country Status (22)

Country Link
US (1) US20150259295A1 (enExample)
EP (1) EP2864294A1 (enExample)
JP (1) JP2015520201A (enExample)
KR (1) KR20150011003A (enExample)
CN (1) CN104411690A (enExample)
AU (1) AU2013279510A1 (enExample)
BR (1) BR112014031108A2 (enExample)
CA (1) CA2869602A1 (enExample)
CL (1) CL2014003242A1 (enExample)
CO (1) CO7160077A2 (enExample)
CR (1) CR20140516A (enExample)
EA (1) EA201492283A1 (enExample)
HK (1) HK1206341A1 (enExample)
IL (1) IL236091A0 (enExample)
IN (1) IN2014DN09347A (enExample)
MA (1) MA37765A1 (enExample)
MX (1) MX2014014105A (enExample)
PE (1) PE20142445A1 (enExample)
PH (1) PH12014502364A1 (enExample)
SG (1) SG11201407229UA (enExample)
UA (1) UA109867C2 (enExample)
WO (1) WO2013189862A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104066729A (zh) 2011-08-15 2014-09-24 英特穆恩公司 溶血磷脂酸受体拮抗剂
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
US10023554B2 (en) 2014-06-27 2018-07-17 Ube Industries, Ltd. Halogen-substituted heterocyclic compound salt
EA202091500A1 (ru) * 2017-12-19 2020-09-14 Бристол-Маерс Сквибб Компани Пиразол n-связанные карбамоилциклогексильные кислоты в качестве антагонистов lpa
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2021282986B2 (en) 2020-06-03 2024-03-07 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20240005892A (ko) 2021-05-11 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
AU2022405082B2 (en) 2021-12-08 2025-09-25 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
CN102245584A (zh) * 2008-12-15 2011-11-16 艾米拉制药公司 溶血磷脂酶受体的拮抗剂
CN102459204A (zh) * 2009-06-03 2012-05-16 艾米拉医药股份有限公司 溶血磷脂酸受体的多环拮抗剂
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080249154A1 (en) * 2003-12-26 2008-10-09 Ono Pharmaceutical Co., Ltd. Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
CN104066729A (zh) * 2011-08-15 2014-09-24 英特穆恩公司 溶血磷脂酸受体拮抗剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245584A (zh) * 2008-12-15 2011-11-16 艾米拉制药公司 溶血磷脂酶受体的拮抗剂
CN102459204A (zh) * 2009-06-03 2012-05-16 艾米拉医药股份有限公司 溶血磷脂酸受体的多环拮抗剂
WO2011017350A2 (en) * 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JS SWANEY,等: "A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model", 《BRITISH JOURNAL OF PHARMACOLOGY》, vol. 160, no. 7, 31 December 2010 (2010-12-31), pages 1699 - 1713 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
WO2020147739A1 (zh) * 2019-01-15 2020-07-23 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN112771027A (zh) * 2019-01-15 2021-05-07 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
CN112771027B (zh) * 2019-01-15 2024-03-05 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
US12377083B2 (en) 2019-01-15 2025-08-05 Wuhan Ll Science And Technology Development Co., Ltd. Lysophosphatidic acid receptor antagonist and preparation method therefor

Also Published As

Publication number Publication date
UA109867C2 (ru) 2015-10-12
EA201492283A1 (ru) 2015-04-30
PH12014502364A1 (en) 2015-01-12
KR20150011003A (ko) 2015-01-29
EP2864294A1 (en) 2015-04-29
CA2869602A1 (en) 2013-12-27
CR20140516A (es) 2014-12-01
MA37765A1 (fr) 2017-04-28
CL2014003242A1 (es) 2015-03-20
US20150259295A1 (en) 2015-09-17
PE20142445A1 (es) 2015-01-28
IN2014DN09347A (enExample) 2015-07-17
IL236091A0 (en) 2015-02-01
AU2013279510A1 (en) 2014-10-16
JP2015520201A (ja) 2015-07-16
MX2014014105A (es) 2015-03-05
HK1206341A1 (en) 2016-01-08
BR112014031108A2 (pt) 2017-06-27
CO7160077A2 (es) 2015-01-15
WO2013189862A1 (en) 2013-12-27
SG11201407229UA (en) 2014-12-30

Similar Documents

Publication Publication Date Title
CN104411690A (zh) 作为lpar拮抗剂的取代的吡唑化合物
US9321738B2 (en) N-alkyltriazole compounds as LPAR antagonists
CN1867551B (zh) 作为前列腺素e2拮抗剂的苯基或吡啶基酰胺化合物
JP4098249B2 (ja) ブラジキニン拮抗薬として有用なメチル上に置換基を有するｎ−ビフェニルメチルアミノシクロアルカンカルボキサミド誘導体
TWI426910B (zh) Cetp抑制劑，醫藥組合物及其用途
HK1206339A1 (en) N-aryltriazole compounds as lpar antagonists
JP6854386B2 (ja) リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物
TW202128644A (zh) 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途
TW201043603A (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
JP5329656B2 (ja) イミダゾリジン誘導体
US7790754B2 (en) Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
US7332499B2 (en) Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
CN101981009B (zh) 作为hdl-胆固醇升高剂的2-三氟甲基烟酰胺衍生物
WO2017008681A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
ZA200405697B (en) N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykininantagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1206341

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150311

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1206341

Country of ref document: HK